BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 27603551)

  • 1. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
    Failing JJ; Finnes HD; Kottschade LA; Allred JB; Markovic SN
    Melanoma Res; 2016 Dec; 26(6):609-615. PubMed ID: 27603551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study.
    Urun Y; Yasar HA; Turna H; Esin E; Sedef AM; Alkan A; Oksuzoglu B; Ozdemir N; Sendur MN; Sezer A; Kılıckap S; Utkan G; Akman T; Akbulut H; Celik I; Abalı H
    J Oncol Pharm Pract; 2019 Oct; 25(7):1658-1664. PubMed ID: 30400750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.
    Mohr P; Ascierto P; Arance A; McArthur G; Hernaez A; Kaskel P; Shinde R; Stevinson K
    J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):962-971. PubMed ID: 29044660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.
    Russi A; Damuzzo V; Chiumente M; Pigozzo J; Cesca M; Chiarion-Sileni V; Palozzo AC
    J Chemother; 2017 Aug; 29(4):245-251. PubMed ID: 28398170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
    Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
    Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.
    Drysdale E; Peng Y; Nguyen P; Baetz T; Hanna TP
    Melanoma Res; 2019 Dec; 29(6):635-642. PubMed ID: 30789386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
    Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
    Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
    McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
    Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
    Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
    Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
    Martens A; Wistuba-Hamprecht K; Yuan J; Postow MA; Wong P; Capone M; Madonna G; Khammari A; Schilling B; Sucker A; Schadendorf D; Martus P; Dreno B; Ascierto PA; Wolchok JD; Pawelec G; Garbe C; Weide B
    Clin Cancer Res; 2016 Oct; 22(19):4848-4858. PubMed ID: 27169993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.
    Mangana J; Dimitriou F; Braun R; Ludwig S; Dummer R; Barysch MJ
    Melanoma Res; 2019 Dec; 29(6):648-654. PubMed ID: 30870270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
    Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
    J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
    Eggermont AMM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbe C; Ferraresi V; Smylie M; Weber JS; Maio M; Hosein F; de Pril V; Kicinski M; Suciu S; Testori A
    Eur J Cancer; 2019 Sep; 119():1-10. PubMed ID: 31400634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
    Balatoni T; Ladányi A; Fröhlich G; Czirbesz K; Kovács P; Pánczél G; Bence E; Plótár V; Liszkay G
    Pathol Oncol Res; 2020 Jan; 26(1):317-325. PubMed ID: 30225783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.
    Gambichler T; Brown V; Steuke AK; Schmitz L; Stockfleth E; Susok L
    J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):972-977. PubMed ID: 29024038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab.
    Moreira RB; Hamieh L; Gjini E; Lako A; Krajewski KM; Yoon CH; Ott PA
    J Immunother Cancer; 2017 Jul; 5(1):61. PubMed ID: 28716097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
    [No Abstract]   [Full Text] [Related]  

  • 19. Diffuse recurrent cutaneous melanoma of the scalp and neck successfully treated with volumetric modulated arc therapy and concurrent ipilimumab.
    Schmid RK; Harker-Murray A; Niemczyk K; Robbins JR
    Pract Radiat Oncol; 2018; 8(3):174-178. PubMed ID: 29122555
    [No Abstract]   [Full Text] [Related]  

  • 20. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
    Tarhini A; Lin Y; Lin H; Rahman Z; Vallabhaneni P; Mendiratta P; Pingpank JF; Holtzman MP; Yusko EC; Rytlewski JA; Rao UNM; Ferris RL; Kirkwood JM
    J Immunother Cancer; 2018 Oct; 6(1):112. PubMed ID: 30352626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.